AbbVie says Phase 1 ABBV-295 study shows up to about 10% mean weight loss over three months
ABBV•AbbVie said all dosing regimens in its Phase 1 ABBV-295 study resulted in least-squares mean weight loss of up to about 10% over three months; 82.2% of treated participants reported mild adverse events as their highest severity.
1. Phase 1 study results
AbbVie said all ABBV-295 dosing regimens resulted in least-squares mean weight loss of up to about 10% over the three-month treatment period. The company said 82.2% of treated participants reported mild adverse events as their highest reported severity.
